
ASHPOfficial is the premier podcast of ASHP and the collective voice of our 50,000 members in health-system pharmacy. Through interviews and discussions with pharmacy thought leaders, ASHPOfficial will explore issues related to public health, medication use, and supporting the professional practice of pharmacists in hospitals, health systems, ambulatory clinics, and other settings. To learn more about ASHP, please visit ashp.org.
Episodes

Thursday May 01, 2025
Thursday May 01, 2025
Sodium Glucose Cotransporter-2 Inhibitors (SGLT2) have demonstrated improvement in patient outcomes across several disease states including patients with type 2 diabetes, heart failure and chronic kidney disease. Despite guideline recommendations for the use of these agents in each of these disease states, utilization of SGLT2 remains relatively low. This podcast discusses some of the barriers to utilization of SGLT2 and strategies to increase uptake of this therapy among patients with diabetes, heart failure and chronic kidney disease.
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.